Conference Day One | Wednesday, December 4
7:20 am Morning Coffee & Check In
8:20 am Chair’s Opening Remarks
Spotlighting Breakthrough Clinical Success for Personalized Cancer Vaccines Toward the Next Best Approval
8:30 am Developing a Patient Specific Dendritic Cell Immunotherapy that Shows Effective Patient Response
Synopsis
- Developing a personal, precision medicine that minimizes adverse events and maximizes efficacy
- Employing a pan-antigenic approach to protect against mutation-associated loss of function for more powerful therapeutics vaccines
- Diving into promising data from cancer trials includes safety, induction of immune responses, tumor regressions, and increased progression free and overall survival of patients
9:00 am Goldspire™: A Biologic-Device Combination Immunotherapy that Induces Preclinical Anti-Tumor Responses Against Multiple Solid Tumors Shows Clinical Activity in Glioblastoma
Synopsis
- Utilizing a biodiffusion chamber releasing tumor antigens and an IGF1R antisense for effective treatment of glioblastoma
- Realizing the platform configuration to maximize immunogenic cell death
- Exploring long-term survival and immunity of glioblastoma patients receiving individualized immunotherapy
9:30 am Personalized Therapeutics Cancer Vaccines for Treating Advanced Cancer – Efficacy in Liver Cancer
Synopsis
- Utilizing DNA-based cancer vaccines that can encode for up to 40 neoantigens to achieve powerful T cell response
- Employing personalized cancer vaccines in an advanced cancer setting to shrink tumors
- Exploring correlative biomarker analyses to understand vaccine efficacy
10:00 am Morning Break & Speed Networking
Synopsis
This networking session is your opportunity to get face-to-face with many of the brightest minds working in the personalized cancer vaccine field and establish meaningful business relationships to pursue for the rest of the conference.
Exploring Computational Methods to Identify the Relevant Antigens & Neoantigens to Find the Best Targets for Personalized Cancer Vaccines
11:00 am Investigating Novel Dark Antigen Targets to Produce More Effective Cancer Vaccines
Synopsis
- Deploying a computational platform to measure the expression and presentation of repetitive targets
- Exploring the repeatome to identify tumor-specific repeats and find ideal targets for cancer vaccines
- Comparing tumor expressed neoantigens in public and private data for platform and target validation
11:30 am NeoPeptides™ Streamlining Manufacturing for Personalized Cancer Vaccines – Current & Future Perspectives
Synopsis
- Manufacture for PCVs remains a relatively niche area with pockets of true expertise
- Innovation in manufacturing methods and regulatory requirements required to meet clinical requirements
- Assuming future clinical success; how will the supply chain deliver?
12:00 pm Developing the DeepNovo Platform to Determine the Most Immunogenic Peptides to Create an Immune Response to Personalized Cancer Vaccines
Synopsis
- Finding novo sequences by de novo mass spectrometry sequencing to determine better neoantigen targets
- Employing AI in proteomics to discover peptides with immunogenicity for more effective cancer vaccines
- Confirming the power of bioinformatics in neoantigen detection and validation by experimental methods for best patient response to individualized cancer vaccines
12:30 pm Networking Lunch Break
Advancing Development of DNA-Based Cancer Vaccines for Maximum Neoantigen Expression & Immune Response
1:30 pm Utilizing a Modality-Agnostic Platform for a Head-to-Head Comparison of mRNA & DNA-based Personalized Cancer Vaccines in Creating an Immune Response
Synopsis
- Comparing DNA and mRNA as modalities to encode for fusion proteins in individualized cancer vaccines to effectively induce an immune response
- Utilizing a unique bioinformatics platform to target immunogenic APCs in personalized cancer vaccines for better tumor control
- Exploring DNA-based personalized cancer vaccines that produce differentiated and more effective T-cells
2:00 pm Synthetic, Enzymatically Produced DNA For Use in DNA & mRNA Vaccines
Synopsis
- 4bbDNA™ confers safety benefits, enables dose reduction and reduced timelines of GMP-grade material over plasmid DNA for both DNA and mRNA vaccine applications use in vaccine applications
- A collaboration with Neomatrix on neoantigen DNA cancer vaccines using hpDNA™ constructs showed meaningful immune responses and reduced tumour growth as compared to pDNA in clinically relevant models – phase I clinical trial anticipated for H125
- mRNA produced from 4basebio’s opDNA™ templates in combination with Hermes™ nanoparticle delivery system shows enhanced immune response and reduced tumour growth comparable to conventional LNP delivery systems in several mouse models
2:30 pm Combining DNA Cancer Vaccines with Checkpoint Inhibitors to Induce an Immune Response in the Tumor & Have a Positive Patient Response
Synopsis
- Enhancing the efficacy of DNA cancer vaccines using checkpoint inhibitors as standard of care to induce a strong immune response
- Exploring self-adjuvanted therapies with personalized cancer vaccines for best patient response
- Employing a double-edged sword of checkpoint inhibitors and the high peptide capability of DNA-based cancer vaccines as effective therapies
3:00 pm Afternoon Break & Poster Session
Synopsis
Contribute to the conversation and share your cutting-edge research with your fellow personalized cancer vaccine community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*
*Please visit the website for the T&Cs for presenting a poster
Discovering Other Modalities in Cancer Vaccines for Increased Safety, Targeted Delivery, & More Effective Vaccines
4:00 pm AccuTOX-Reprogrammed Mesenchymal Stromal Cells (ARM-X): An Alternative Cellular Vector for Cancer Immunotherapy
Synopsis
- Reprogramming mesenchymal stromal cells in individualized cancer vaccines to present antigens to the immune system
- Employing a fast design and manufacture method of personalized cancer vaccines that is applicable to many indications for effective tumor control
- Unearthing the use of cancer vaccines with checkpoint inhibitors for hard-to-treat cancers
4:30 pm Personalized Cancer Vaccines Need Personalized Manufacturing
Synopsis
- Demonstrating the Nutcracker® Manufacturing Unit (NMU) – Amplifying a DNA template, transcribing it into RNA in vitro, and packaging into a proprietary nanoparticle – and miniaturizing them into fully enclosed microfluidics pathways on biochips
- Showcasing the advantages a microfluidics approach with the NMU for the nanoscale volumes that RNA is manufactured in
- Unlocking the NMU’s potential to excel in creating personalized medicines and scalability for treatments intended for hundreds of thousands of patients
5:00 pm Uncovering the Best Strategies to Employ Neoantigen Vaccines for the Most Effective Therapies
Synopsis
- Utilizing marine models to identify the patient profiles that are most effective for personalized cancer vaccines
- Exploring the timing and dosage schedule of personalized cancer vaccines to improve translation to the clinic
- Determining the optimal combination therapy strategy with personalized vaccines for better cancer treatment
5:30 pm New Class of Antigen-Specific Cancer Active Immunotherapies Based on a Potent Presenting Cell Line (PDC*line)
Synopsis
- PDC*line is a new potent and scalable therapeutic cancer vaccine based on a proprietary allogeneic cell line of plasmacytoid dendritic cells
- Presentation of the first results of the ongoing phase I/II clinical trial for NSCLC patients
- Initiation of a phase Ib clinical trial with a personalized neoantigen-based vaccine in CRC patients